November 2024
New York
Midtown Financial (MiFi)
STIMIT live on New York Time Square
STIMIT live on New York Time Square
BIEL, Switzerland, Nov. 20, 2024 – STIMIT AG announced today it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, “STIMIT ACTIVATOR 1 PIVOTAL STUDY,” with world renowned clinical centers. STIMIT’s initial therapy in its platform uses noninvasive diaphragm neurostimulation and is designed to preserves diaphragm thickness in patients
who are on invasive mechanical ventilation (MV) and thus are at risk of diaphragmatic
dysfunction/atrophy. The IDE study will evaluate the safety and effectiveness of the technology for this indication.
ASAIO’s mission is to provide a forum that globally and collaboratively promotes the development of innovative medical device technology at the crossroads of science, engineering, and medicine. This is synergistically accomplished by our interdisciplinary and talented membership comprised of clinicians, scientists, engineers, industry, academia, the financial community, as well as representatives from the FDA, National Science Foundation and the NIH.
At the edge of life, there is a wisdom of gratitude and appreciation of life, that creates unity. A special place where doctors, engineers, medical & regulatory & entrepreneurial & company professionals unite: ASAIO congress.
@ Boris Adolf Photography
Every year, the Technopark Zurich Foundation and Zürcher Kantonalbank award a prize to a technical project on the threshold of market entry. STIMIT was a finalist and received a prize worth CHF 10,000. The ZKB Pionierpreis Technopark Award is one of the most prestigious innovation prizes for start-ups in Switzerland.
The Charite Team (Prof. Dr. Stefan Schaller stefan.schaller@charite.de; Dr. Alessandro Panelli Alessandro.Panelli@Charite.de) published “First non-invasive magnetic phrenic nerve and diaphragm stimulation in anaesthetized patients: a proof-of-concept study” (STIMIT I) being selected by ESICM in the category “Paper of the Year in Translational Biology”. Also, Charite published STIMIT II ICU trial on ESICM (Abstract) on the ESICM congress.
Interview with Paper-Author Prof. Schaller: Online Interview (just click on this link to view video online)
(full publication in progress)
Mechanical ventilation in intensive care causes degeneration of the breathing muscle. STIMIT AG and ETH Zürich pursue a pioneering approach with non-invasive stimulators. Ronja Müller-Bruhn and Prof. Christina Spengler give insight into their collaboration.
Hosted by the American Thoracic Society, the 2024 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways. This meeting historically attracts 350+ global leaders representing all facets of the respiratory industry, including representatives from start-ups, business development, venture capital, government, academia and clinical medicine.
STIMIT is the winners of the Swiss Excellence Product Award 2022 in the category start-up. This is the 10th time that the jury of the Swiss Excellence Foundation has honored innovative Swiss products.
This year, 30 companies applied with their products for the Swiss Excellence Product Award. The jury visited the shortlisted candidates over the past few months and selected three finalists in each category. The jury evaluated the innovation content, the value creation potential as well as the quality of the business model and the marketing concept.
STIMIT AG was able to prevail in the Startup category with the STIMIT Activator. The innovative product stimulates the diaphragm muscles of intensive care patients - non-invasively - and thus gets patients breathing who would otherwise not breathe. "The product has great potential. It is already being used successfully, and Stimit has chosen a clever strategy for financing it," explains Stefan Philippi, lecturer at the Institute for Corporate Management at the FHNW and jury member of the Swiss Excellence Foundation in his laudation.
3 Innosuisse Innovation Project Grants
3 Feasibility Project Grants
Venture Kick I, II, III Funding
4 Goverment & Foundation Grants
Aarbergstrasse 46
CH-2503 Biel/Bienne
Switzerland
Email: info@stimit.com
Tel: +41 32 513 93 00
